🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million new cases each year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of rising global incidence, the spread of superbugs and the very limited treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

As per findings released by a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The trial included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Clinicians treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is described as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.